Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia
January 25, 2017 08:05 ET
|
Esperion Therapeutics, Inc.
Approximately 2,000 Patients Enrolled Ahead of Schedule Following Study Expansion in October 2016Global Study Enrolled Patients with Hypercholesterolemia with ASCVD and/or HeFH at High CVD...